Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC, Tóth E, Kiss O, Rusz O, Cserni G, Zombori T, Székely B, Kulka J, Tímár J, Csabai I, Szallasi Z. Diossy M, et al. Among authors: solimeno c. Ann Oncol. 2018 Sep 1;29(9):1948-1954. doi: 10.1093/annonc/mdy216. Ann Oncol. 2018. PMID: 29917049 Free PMC article.
Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling.
Denkert C, Romey M, Swedlund B, Hattesohl A, Teply-Szymanski J, Kommoss S, Kaiser K, Staebler A, du Bois A, Grass A, Knappmeyer C, Heitz F, Solimeno C, Ebel T, Harter P, Marmé F, Jank P, Gaiser T, Neff C, Wagner U, Timms KM, Rodepeter F. Denkert C, et al. Among authors: solimeno c. J Mol Diagn. 2022 Dec;24(12):1254-1263. doi: 10.1016/j.jmoldx.2022.09.004. Epub 2022 Sep 30. J Mol Diagn. 2022. PMID: 36191839 Free article.
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Lenz L, Neff C, Solimeno C, Cogan ES, Abramson VG, Boughey JC, Falkson C, Goetz MP, Ford JM, Gradishar WJ, Jankowitz RC, Kaklamani VG, Marcom PK, Richardson AL, Storniolo AM, Tung NM, Vinayak S, Hodgson DR, Lai Z, Dearden S, Hennessy BT, Mayer EL, Mills GB, Slavin TP, Gutin A, Connolly RM, Telli ML, Stearns V, Lanchbury JS, Timms KM. Lenz L, et al. Among authors: solimeno c. Breast Cancer Res Treat. 2023 Nov;202(1):191-201. doi: 10.1007/s10549-023-07046-3. Epub 2023 Aug 17. Breast Cancer Res Treat. 2023. PMID: 37589839 Free PMC article.
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W. Kaklamani VG, et al. Among authors: solimeno c. Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26. Breast Cancer Res Treat. 2015. PMID: 26006067 Clinical Trial.
Corrigendum to: Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC, Tóth E, Kiss O, Rusz O, Cserni G, Zombori T, Székely B, Kulka J, Tímár J, Csabai I, Szallasi Z. Diossy M, et al. Among authors: solimeno c. Ann Oncol. 2019 Aug 1;30(8):1406. doi: 10.1093/annonc/mdz081. Ann Oncol. 2019. PMID: 30929001 Free PMC article. No abstract available.